HEMAY PHARMA-B
0005418AOpen醫療健康 · 公司为生物医药企业，核心产品Mufemilast是一种口服PDE4抑制剂，用于银屑病、白塞病及特应性皮炎等自身免疫和炎症性疾病的治疗，并拥有临床阶段候选药物。
HEMAY PHARMA-B (00054) is a open Hong Kong IPO. This page brings together the offer price, entry fee, subscription timeline, grey-market context, allotment data and stage-based reference research in one place.
- Offer price
- HK$18.90
- Final offer price
- HK$18.90
- One-lot win rate
- 21.2%
- Proceeds
- HK$1.04B
- Public oversub.
- —
Predicted
Lot / entry fee 100 shares · HK$2K · Sponsor SDIC Securities
- Offer starts Oct 30
- /Offer closes Nov 4Now
- /Grey market Nov 6
- /Listing Nov 9
SubscriptionHEMAY PHARMA-B: subscription-stage reference
The subscription stage draws on the prospectus, sponsor record and early public filings. Allotment results and grey-market prints have not occurred yet.
Current- Reference rating
- Cautious
- Reference score
- 51
- Forecast grey range
- -10.5% – +114.4%
Data updated · Oct 30, 2026, 18:41 HKT
View factors and research
The assessment and probability ranges are informational only and are not investment advice.
AI Research Report
SubscriptionPre-greyHEMAY PHARMA-B: pre-grey-market reference
The pre-grey stage includes published allotment and public oversubscription data. Grey-market prints are not yet reflected here.
Pending- Reference rating
- Cautious
- Reference score
- 51
- Forecast grey range
- -10.5% – +114.4%
Post-greyHEMAY PHARMA-B: post-grey-market reference
The post-grey stage includes grey-market price and turnover observations. Listing-day results still follow official trading and company announcements.
Pending- Reference rating
- Cautious
- Reference score
- 51
- Forecast first-day range
- -10.5% – +114.4%
This IPO has not listed yet. The current score is a stage-based estimate, may still be incomplete or inaccurate, and will adjust as allocation, grey-market, and listing data become available.
HEMAY PHARMA-B: grey-market trend
HEMAY PHARMA-B: predicted allotment
Data updated · Oct 30, 2026, 18:42 HKT
Only key tiers are shown here. Full tiers and other allotment-pattern comparisons are on the allotment-odds page.
- 1 lot
- 21.2%
- A tail · Apply 2,000 lots
- Sign in to view
- B head · Apply 3,000 lots
- Sign in to view
- Top hammer
- Sign in to view
Predicted
Predicted
Predicted
Predicted
How to read this page
These answers combine this IPO’s published figures with clearly labeled model estimates. They explain how to read the modules above and are not investment advice.
What is the one-lot allotment rate for HEMAY PHARMA-B?
The IPO is still in its offer period, so there is no official one-lot rate yet. This site's current model estimate is about 21.2%; the company allotment announcement is final.
What is the difference between A-tail and B-head for HEMAY PHARMA-B?
Based on the prospectus's legal application tiers, A-tail is 2,000 lots and B-head is 3,000 lots, representing about HK$3.8M and HK$5.7M of application principal. Pool A and Pool B are allocated separately, so application size alone does not show capital efficiency.
Can the grey-market price of HEMAY PHARMA-B be treated as the listing price?
Grey-market trading is dated Nov 6. Before that session there is no print to cite. Even after quotes appear, they are not the official listing price.
Why does HEMAY PHARMA-B have three reference ratings?
The current status is "Open", so start with the subscription section. Subscription, pre-grey and post-grey each use only the public information available at that point, so the score can change. Labels are high attention / neutral / caution only — informational comparison, not a buy or subscribe call.